{
  "events": [
    {
      "id": "EVT-2026-001",
      "type": "pdufa",
      "ticker": "AQST",
      "catalyst": "FDA decision on AQST-109 (epinephrine) for emergency treatment of allergic reactions",
      "date": "2026-01-06",
      "date_type": "hard",
      "archetype": "pdufa",
      "status": "tracking",
      "notes": "Standard review, NDA filing",
      "linked_idea": null,
      "source": "CatalystAlert PDUFA calendar",
      "discovered_date": "2025-12-30"
    },
    {
      "id": "EVT-2026-002",
      "type": "pdufa",
      "ticker": "TVTX",
      "catalyst": "FDA decision on sparsentan for focal segmental glomerulosclerosis (FSGS)",
      "date": "2026-01-13",
      "date_type": "hard",
      "archetype": "pdufa",
      "status": "tracking",
      "notes": "Priority review, sNDA filing for FSGS indication. IgA nephropathy already approved.",
      "linked_idea": null,
      "source": "CatalystAlert PDUFA calendar, BPIQ",
      "discovered_date": "2025-12-30"
    },
    {
      "id": "EVT-2026-003",
      "type": "pdufa",
      "ticker": "AQST",
      "catalyst": "FDA decision on Anaphylm (epinephrine sublingual film) for emergency treatment of anaphylaxis",
      "date": "2026-01-31",
      "date_type": "hard",
      "archetype": "pdufa",
      "status": "tracking",
      "notes": "Priority review",
      "linked_idea": null,
      "source": "CatalystAlert PDUFA calendar",
      "discovered_date": "2025-12-30"
    },
    {
      "id": "EVT-2026-004",
      "type": "pdufa",
      "ticker": "ASND",
      "catalyst": "FDA decision on TransCon CNP (navepegritide) for achondroplasia",
      "date": "2026-02-28",
      "date_type": "hard",
      "archetype": "pdufa",
      "status": "tracking",
      "notes": "Rare disease treatment",
      "linked_idea": null,
      "source": "Web search - PDUFA calendar",
      "discovered_date": "2025-12-30"
    },
    {
      "id": "EVT-2026-005",
      "type": "pdufa",
      "ticker": "ALDX",
      "catalyst": "FDA decision on reproxalap for dry eye disease",
      "date": "2026-03-16",
      "date_type": "hard",
      "archetype": "pdufa",
      "status": "tracking",
      "notes": "Extended PDUFA date from original deadline",
      "linked_idea": null,
      "source": "Web search - PDUFA calendar",
      "discovered_date": "2025-12-30"
    },
    {
      "id": "EVT-2026-006",
      "type": "pdufa",
      "ticker": "BMY",
      "catalyst": "FDA decision on deucravacitinib (Sotyktu) for psoriatic arthritis",
      "date": "2026-03-06",
      "date_type": "hard",
      "archetype": "pdufa",
      "status": "tracking",
      "notes": "Label expansion for existing approved drug",
      "linked_idea": null,
      "source": "Web search - PDUFA calendar",
      "discovered_date": "2025-12-30"
    },
    {
      "id": "EVT-2026-007",
      "type": "pdufa",
      "ticker": "GSK",
      "catalyst": "FDA decision on linerixibat for cholestatic pruritus in primary biliary cholangitis",
      "date": "2026-03-24",
      "date_type": "hard",
      "archetype": "pdufa",
      "status": "tracking",
      "notes": "Rare disease indication",
      "linked_idea": null,
      "source": "Web search - PDUFA calendar",
      "discovered_date": "2025-12-30"
    },
    {
      "id": "EVT-2026-008",
      "type": "merger",
      "ticker": "AVDX",
      "catalyst": "Novartis acquisition of Avidity Biosciences expected to close",
      "date": "2026-06-30",
      "date_type": "soft",
      "archetype": "merger_arb",
      "status": "tracking",
      "notes": "$12B acquisition, $72/share (46% premium). Expected close in 2026, exact date TBD",
      "linked_idea": null,
      "source": "FiercePharma M&A coverage",
      "discovered_date": "2025-12-30"
    },
    {
      "id": "EVT-2026-009",
      "type": "merger",
      "ticker": "AKRO",
      "catalyst": "Novo Nordisk acquisition of Akero Therapeutics - COMPLETED",
      "date": "2025-12-09",
      "date_type": "hard",
      "archetype": "merger_arb",
      "status": "completed",
      "notes": "$4.7B acquisition, $54/share + $6 CVR. MASH treatment focus. Deal closed Dec 9, 2025. AKRO delisted, now Novo subsidiary.",
      "linked_idea": null,
      "source": "PwC M&A outlook, Akero IR",
      "discovered_date": "2025-12-30",
      "close_date": "2025-12-09"
    },
    {
      "id": "EVT-2026-010",
      "type": "merger",
      "ticker": "CLRS",
      "catalyst": "Thermo Fisher acquisition of Clario expected to close",
      "date": "2026-06-30",
      "date_type": "soft",
      "archetype": "merger_arb",
      "status": "tracking",
      "notes": "$9.4B acquisition. Expected close early to mid-2026",
      "linked_idea": null,
      "source": "AllianceBernstein M&A analysis",
      "discovered_date": "2025-12-30"
    },
    {
      "id": "EVT-2026-011",
      "type": "merger",
      "ticker": "HALD",
      "catalyst": "Johnson & Johnson acquisition of Halda Therapeutics expected to close",
      "date": "2026-03-31",
      "date_type": "soft",
      "archetype": "merger_arb",
      "status": "tracking",
      "notes": "$3.05B acquisition. Expected close Q1 2026",
      "linked_idea": null,
      "source": "Expert Market Research",
      "discovered_date": "2025-12-30"
    },
    {
      "id": "EVT-2026-012",
      "type": "spinoff",
      "ticker": "CMCSA",
      "catalyst": "Comcast spin-off of Versant Media Group distribution",
      "date": "2026-01-02",
      "date_type": "hard",
      "archetype": "spinoff",
      "status": "tracking",
      "notes": "Record date 12/16/2025, distribution 1/2/2026, regular-way trading begins 1/5/2026",
      "linked_idea": null,
      "source": "Comcast investor relations",
      "discovered_date": "2025-12-30"
    },
    {
      "id": "EVT-2026-013",
      "type": "spinoff",
      "ticker": "HON",
      "catalyst": "Honeywell separation of Aerospace and Automation divisions",
      "date": "2026-09-30",
      "date_type": "soft",
      "archetype": "spinoff",
      "status": "tracking",
      "notes": "Projected for second half of 2026. Two separate spinoffs planned",
      "linked_idea": null,
      "source": "StockSpinoffs.com",
      "discovered_date": "2025-12-30"
    },
    {
      "id": "EVT-2026-014",
      "type": "spinoff",
      "ticker": "MIDD",
      "catalyst": "Middleby Corporation spin-off of Industrial Processing Division",
      "date": "2026-03-31",
      "date_type": "soft",
      "archetype": "spinoff",
      "status": "tracking",
      "notes": "Tax-free transaction. Expected completion by early 2026",
      "linked_idea": null,
      "source": "InsideArbitrage spinoff tracker",
      "discovered_date": "2025-12-30"
    },
    {
      "id": "EVT-2026-015",
      "type": "activist",
      "ticker": "NCPL",
      "catalyst": "Strategic EP LLC filed 13D pursuing strategic deal to maximize shareholder value",
      "date": "2025-12-02",
      "date_type": "hard",
      "archetype": "activist",
      "status": "tracking",
      "notes": "Recent 13D filing. Activist pursuing accretive transaction opportunities",
      "linked_idea": null,
      "source": "GlobeNewswire 13D filing announcement",
      "discovered_date": "2025-12-30"
    },
    {
      "id": "EVT-2026-016",
      "type": "pdufa",
      "ticker": "SNY",
      "catalyst": "FDA decision on Cerezyme (imiglucerase) sBLA for Gaucher disease update",
      "date": "2026-01-13",
      "date_type": "hard",
      "archetype": "pdufa",
      "status": "tracking",
      "notes": "Supplemental BLA; lower-volatility label/manufacturing update",
      "linked_idea": null,
      "source": "User report: Event-Driven Alpha: Strategic Catalyst Outlook (H1 2026)",
      "discovered_date": "2025-12-30"
    },
    {
      "id": "EVT-2026-017",
      "type": "pdufa",
      "ticker": "PHAR",
      "catalyst": "FDA decision on leniolisib (Joenja) sNDA for APDS/related immunology expansion",
      "date": "2026-01-31",
      "date_type": "hard",
      "archetype": "pdufa",
      "status": "tracking",
      "notes": "Pharming Group (Euronext: PHAR) label expansion timing cited in report",
      "linked_idea": null,
      "source": "User report: Event-Driven Alpha: Strategic Catalyst Outlook (H1 2026)",
      "discovered_date": "2025-12-30"
    },
    {
      "id": "EVT-2026-018",
      "type": "pdufa",
      "ticker": "ALNY",
      "catalyst": "FDA decision on Amvuttra (vutrisiran) sNDA for ATTR-CM",
      "date": "2026-03-23",
      "date_type": "hard",
      "archetype": "pdufa",
      "status": "tracking",
      "notes": "HELIOS-B data; potential label expansion into cardiomyopathy",
      "linked_idea": null,
      "source": "User report: Event-Driven Alpha: Strategic Catalyst Outlook (H1 2026)",
      "discovered_date": "2025-12-30"
    },
    {
      "id": "EVT-2026-019",
      "type": "pdufa",
      "ticker": "BIIB",
      "catalyst": "FDA decision on Leqembi subcutaneous formulation for Alzheimer's disease",
      "date": "2026-03-31",
      "date_type": "soft",
      "archetype": "pdufa",
      "status": "tracking",
      "notes": "Targeted for March 2026; Eisai partner",
      "linked_idea": null,
      "source": "User report: Event-Driven Alpha: Strategic Catalyst Outlook (H1 2026)",
      "discovered_date": "2025-12-30"
    },
    {
      "id": "EVT-2026-020",
      "type": "pdufa",
      "ticker": "REPL",
      "catalyst": "FDA decision on RP1 (vusolimogene oderparepvec) for advanced melanoma",
      "date": "2026-04-10",
      "date_type": "hard",
      "archetype": "pdufa",
      "status": "tracking",
      "notes": "Oncolytic virus platform; post-PD-1 refractory setting",
      "linked_idea": null,
      "source": "User report: Event-Driven Alpha: Strategic Catalyst Outlook (H1 2026)",
      "discovered_date": "2025-12-30"
    },
    {
      "id": "EVT-2026-021",
      "type": "pdufa",
      "ticker": "XSPR",
      "catalyst": "FDA decision on XS003 (nilotinib) for chronic myeloid leukemia",
      "date": "2026-06-18",
      "date_type": "hard",
      "archetype": "pdufa",
      "status": "tracking",
      "notes": "505(b)(2) reformulation with improved dosing convenience",
      "linked_idea": null,
      "source": "User report: Event-Driven Alpha: Strategic Catalyst Outlook (H1 2026)",
      "discovered_date": "2025-12-30"
    },
    {
      "id": "EVT-2026-022",
      "type": "spinoff",
      "ticker": "APTV",
      "catalyst": "Aptiv spin-off of Cyprium (EDS wiring business)",
      "date": "2026-03-31",
      "date_type": "soft",
      "archetype": "spinoff",
      "status": "tracking",
      "notes": "Separation of EDS business; expected end of Q1 2026",
      "linked_idea": null,
      "source": "User report: Event-Driven Alpha: Strategic Catalyst Outlook (H1 2026)",
      "discovered_date": "2025-12-30"
    },
    {
      "id": "EVT-2026-023",
      "type": "spinoff",
      "ticker": "SPGI",
      "catalyst": "S&P Global spin-off of Mobility division",
      "date": "2026-06-30",
      "date_type": "soft",
      "archetype": "spinoff",
      "status": "tracking",
      "notes": "Targeted for Q2 2026",
      "linked_idea": null,
      "source": "User report: Event-Driven Alpha: Strategic Catalyst Outlook (H1 2026)",
      "discovered_date": "2025-12-30"
    },
    {
      "id": "EVT-2026-024",
      "type": "spinoff",
      "ticker": "FDX",
      "catalyst": "FedEx spin-off of FedEx Freight",
      "date": "2026-06-30",
      "date_type": "soft",
      "archetype": "spinoff",
      "status": "tracking",
      "notes": "Targeted for June 2026",
      "linked_idea": null,
      "source": "User report: Event-Driven Alpha: Strategic Catalyst Outlook (H1 2026)",
      "discovered_date": "2025-12-30"
    },
    {
      "id": "EVT-2026-025",
      "type": "merger",
      "ticker": "HFWA",
      "catalyst": "Heritage Financial acquisition of Olympic Bancorp expected to close",
      "date": "2026-01-31",
      "date_type": "hard",
      "archetype": "merger_arb",
      "status": "tracking",
      "notes": "Regulatory approval received; targeted close date cited in report",
      "linked_idea": null,
      "source": "User report: Event-Driven Alpha: Strategic Catalyst Outlook (H1 2026)",
      "discovered_date": "2025-12-30"
    },
    {
      "id": "EVT-2026-026",
      "type": "merger",
      "ticker": "OCFC",
      "catalyst": "OceanFirst acquisition of Flushing Financial expected to close",
      "date": "2026-06-30",
      "date_type": "soft",
      "archetype": "merger_arb",
      "status": "tracking",
      "notes": "All-stock merger; targeted for Q2 2026",
      "linked_idea": null,
      "source": "User report: Event-Driven Alpha: Strategic Catalyst Outlook (H1 2026)",
      "discovered_date": "2025-12-30"
    },
    {
      "id": "EVT-2026-027",
      "type": "merger",
      "ticker": "ONTF",
      "catalyst": "Cvent acquisition of ON24 expected to close",
      "date": "2026-06-30",
      "date_type": "soft",
      "archetype": "merger_arb",
      "status": "tracking",
      "notes": "Take-private; targeted for H1 2026",
      "linked_idea": null,
      "source": "User report: Event-Driven Alpha: Strategic Catalyst Outlook (H1 2026)",
      "discovered_date": "2025-12-30"
    },
    {
      "id": "EVT-2026-028",
      "type": "merger",
      "ticker": "SOAR",
      "catalyst": "Volato Group merger with M2i Global expected to close",
      "date": "2026-03-31",
      "date_type": "soft",
      "archetype": "merger_arb",
      "status": "tracking",
      "notes": "Reverse merger; S-4 filed December 2025",
      "linked_idea": null,
      "source": "User report: Event-Driven Alpha: Strategic Catalyst Outlook (H1 2026)",
      "discovered_date": "2025-12-30"
    },
    {
      "id": "EVT-2026-029",
      "type": "activist",
      "ticker": "LUV",
      "catalyst": "Elliott standstill expiration following Southwest settlement",
      "date": "2026-04-01",
      "date_type": "hard",
      "archetype": "activist",
      "status": "tracking",
      "notes": "Standstill expires April 1, 2026; potential renewed activism",
      "linked_idea": null,
      "source": "User report: Event-Driven Alpha: Strategic Catalyst Outlook (H1 2026)",
      "discovered_date": "2025-12-30"
    },
    {
      "id": "EVT-2026-030",
      "type": "activist",
      "ticker": "LULU",
      "catalyst": "Elliott Management $1B stake with CEO replacement proposal",
      "date": "2026-01-02",
      "date_type": "soft",
      "archetype": "activist",
      "status": "tracking",
      "notes": "Tier-1 activist. Elliott acquired $1B+ stake (Dec 18, 2025) and proposed CEO candidate. High-priority campaign targeting leadership change.",
      "linked_idea": null,
      "source": "CNBC, SEC 13D filing",
      "discovered_date": "2026-01-02",
      "priority": "high",
      "tier": "tier_1"
    },
    {
      "id": "EVT-2026-031",
      "type": "activist",
      "ticker": "CWAN",
      "catalyst": "Starboard Value 5% stake as company reviews strategic options",
      "date": "2025-12-13",
      "date_type": "hard",
      "archetype": "activist",
      "status": "tracking",
      "notes": "Tier-1 activist. Starboard revealed 5% stake (Dec 13, 2025) as Clearwater Analytics reviews strategic options. Potential sale process or operational improvements.",
      "linked_idea": null,
      "source": "CNBC, SEC 13D filing",
      "discovered_date": "2026-01-02",
      "priority": "medium",
      "tier": "tier_1"
    },
    {
      "id": "EVT-2026-032",
      "type": "activist",
      "ticker": "BILL",
      "catalyst": "Starboard Value 8% stake in Bill Holdings",
      "date": "2025-12-01",
      "date_type": "soft",
      "archetype": "activist",
      "status": "tracking",
      "notes": "Tier-1 activist. Starboard took hefty 8% stake in Bill Holdings (payment software company). Potential operational improvements or strategic alternatives.",
      "linked_idea": null,
      "source": "Nasdaq, SEC 13D filing",
      "discovered_date": "2026-01-02",
      "priority": "medium",
      "tier": "tier_1"
    },
    {
      "id": "EVT-2026-033",
      "type": "pdufa",
      "ticker": "ATRA",
      "catalyst": "FDA decision on tabelecleucel for EBV+ PTLD",
      "date": "2026-01-10",
      "date_type": "hard",
      "archetype": "pdufa",
      "status": "tracking",
      "notes": "First-ever allogeneic T-cell therapy if approved. High priority.",
      "linked_idea": null,
      "source": "FDA PDUFA calendar, BPIQ",
      "discovered_date": "2026-01-06",
      "priority": "high"
    },
    {
      "id": "EVT-2026-034",
      "type": "pdufa",
      "ticker": "FBIO",
      "catalyst": "FDA decision on CUTX-101 for Menkes Disease",
      "date": "2026-01-14",
      "date_type": "hard",
      "archetype": "pdufa",
      "status": "tracking",
      "notes": "Rolling NDA submission completed.",
      "linked_idea": null,
      "source": "FDA PDUFA calendar, Fortress Biotech IR",
      "discovered_date": "2026-01-06"
    },
    {
      "id": "EVT-2026-035",
      "type": "merger",
      "ticker": "OS",
      "catalyst": "Hg acquisition of OneStream",
      "date": "2026-06-30",
      "date_type": "soft",
      "archetype": "merger_arb",
      "status": "tracking",
      "notes": "$6.4B definitive agreement. Expected close H1 2026.",
      "linked_idea": null,
      "source": "PR Newswire, OneStream IR",
      "discovered_date": "2026-01-06"
    },
    {
      "id": "EVT-2026-036",
      "type": "merger",
      "ticker": "CMA",
      "catalyst": "Fifth Third Bancorp acquisition of Comerica Incorporated",
      "date": "2026-03-31",
      "date_type": "soft",
      "archetype": "merger_arb",
      "status": "tracking",
      "notes": "Shareholder approval received. Expected close Q1 2026.",
      "linked_idea": null,
      "source": "Business Wire, SEC filings",
      "discovered_date": "2026-01-06"
    },
    {
      "id": "EVT-2026-037",
      "type": "activist",
      "ticker": "SWX",
      "catalyst": "Icahn Group 8.36% stake in Southwest Gas",
      "date": "2026-01-02",
      "date_type": "hard",
      "archetype": "activist",
      "status": "tracking",
      "notes": "Tier-2 activist (Icahn). Recent 13D/A filing showing increased stake. Teno board resignation Dec 31.",
      "linked_idea": null,
      "source": "SEC 13D filing, StockTitan",
      "discovered_date": "2026-01-06",
      "priority": "high",
      "tier": "tier_2"
    },
    {
      "id": "EVT-2026-038",
      "type": "pdufa",
      "ticker": "RGNX",
      "catalyst": "FDA decision on RGX-121 for Hunter Syndrome (MPS II)",
      "date": "2026-02-08",
      "date_type": "hard",
      "archetype": "pdufa",
      "status": "tracking",
      "notes": "Gene therapy candidate.",
      "linked_idea": null,
      "source": "FDA PDUFA calendar, TipRanks",
      "discovered_date": "2026-01-06"
    },
    {
      "id": "EVT-2026-039",
      "type": "pdufa",
      "ticker": "SNY",
      "catalyst": "FDA decision on Dupixent (dupilumab) for new indication",
      "date": "2026-02-28",
      "date_type": "hard",
      "archetype": "pdufa",
      "status": "tracking",
      "notes": "Label expansion for chronic spontaneous urticaria (CSU).",
      "linked_idea": null,
      "source": "FDA PDUFA calendar, Sanofi IR",
      "discovered_date": "2026-01-06"
    }
  ]
}